Photo taken from Julien Mazière/Twitter
Oct 23, 2023, 15:35
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA study from ESMO23 on X/Twitter:
“Another big hit ESMO 23. Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT. Impressive curves and HR 0.24. Immediate practice-changing trial.”
Source: Julien Mazières/Twitter.
